Avapritinib in CBF-AML With KIT Mutations

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 1, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions

Core Binding Factor Acute Myeloid LeukemiaKIT Mutation-Related Tumors

Interventions

DRUG

Avapritinib

administered orally

Trial Locations (1)

RECRUITING

First Affiliated Hospital of Soochow University, Suzhou

All Listed Sponsors

lead

The First Affiliated Hospital of Soochow University

OTHER